Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 224

1.

Multianalyte profiling of serum cytokines for detection of pancreatic cancer.

Zeh HJ, Winikoff S, Landsittel DP, Gorelik E, Marrangoni AM, Velikokhatnaya L, Winans MT, Lee K, Moser A, Bartlett D, Lotze MT, Siegfried JM, Whitcomb D, Papacristou G, Slivka A, Bigbee WL, Lokshin AE.

Cancer Biomark. 2005;1(6):259-69. Erratum in: Cancer Biomark. 2006;2(3-4):175. Papacristou, G [added].

PMID:
17192050
2.

Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9.

Koopmann J, Rosenzweig CN, Zhang Z, Canto MI, Brown DA, Hunter M, Yeo C, Chan DW, Breit SN, Goggins M.

Clin Cancer Res. 2006 Jan 15;12(2):442-6.

3.

Early detection of head and neck cancer: development of a novel screening tool using multiplexed immunobead-based biomarker profiling.

Linkov F, Lisovich A, Yurkovetsky Z, Marrangoni A, Velikokhatnaya L, Nolen B, Winans M, Bigbee W, Siegfried J, Lokshin A, Ferris RL.

Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):102-7.

4.

CEACAM1, a novel serum biomarker for pancreatic cancer.

Simeone DM, Ji B, Banerjee M, Arumugam T, Li D, Anderson MA, Bamberger AM, Greenson J, Brand RE, Ramachandran V, Logsdon CD.

Pancreas. 2007 May;34(4):436-43.

PMID:
17446843
5.

Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry.

Koopmann J, Zhang Z, White N, Rosenzweig J, Fedarko N, Jagannath S, Canto MI, Yeo CJ, Chan DW, Goggins M.

Clin Cancer Res. 2004 Feb 1;10(3):860-8.

6.

Serum heat shock protein 27 is increased in chronic pancreatitis and pancreatic carcinoma.

Liao WC, Wu MS, Wang HP, Tien YW, Lin JT.

Pancreas. 2009 May;38(4):422-6. doi: 10.1097/MPA.0b013e318198281d.

PMID:
19214136
7.

Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.

Jiang XT, Tao HQ, Zou SC.

Hepatobiliary Pancreat Dis Int. 2004 Aug;3(3):464-8.

8.

Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers.

Koopmann J, Buckhaults P, Brown DA, Zahurak ML, Sato N, Fukushima N, Sokoll LJ, Chan DW, Yeo CJ, Hruban RH, Breit SN, Kinzler KW, Vogelstein B, Goggins M.

Clin Cancer Res. 2004 Apr 1;10(7):2386-92.

9.

Serum tumor antigen REG4 as a diagnostic biomarker in pancreatic ductal adenocarcinoma.

Takayama R, Nakagawa H, Sawaki A, Mizuno N, Kawai H, Tajika M, Yatabe Y, Matsuo K, Uehara R, Ono K, Nakamura Y, Yamao K.

J Gastroenterol. 2010;45(1):52-9. doi: 10.1007/s00535-009-0114-y.

PMID:
19789838
10.

Clinical value of serum TAG-72 as a tumor marker for pancreatic carcinoma. Comparison with CA 19-9.

Pasquali C, Sperti C, D'Andrea AA, Costantino V, Filipponi C, Pedrazzoli S.

Int J Pancreatol. 1994 Jun;15(3):171-7.

PMID:
7930777
11.

[Accuracy of imaging techniques and tumor markers in the diagnosis of pancreatic cancer].

Clavé P, Boadas J, González-Carro P, Mora J, Pérez C, Martínez A, Roca M, Lluís F, Farré A.

Gastroenterol Hepatol. 1999 Aug-Sep;22(7):335-41. Spanish.

PMID:
10535205
12.

Serum peptidome profiling revealed platelet factor 4 as a potential discriminating Peptide associated with pancreatic cancer.

Fiedler GM, Leichtle AB, Kase J, Baumann S, Ceglarek U, Felix K, Conrad T, Witzigmann H, Weimann A, Schütte C, Hauss J, Büchler M, Thiery J.

Clin Cancer Res. 2009 Jun 1;15(11):3812-9. doi: 10.1158/1078-0432.CCR-08-2701.

13.

Adiponectin as a potential differential marker to distinguish pancreatic cancer and chronic pancreatitis.

Chang MC, Chang YT, Su TC, Yang WS, Chen CL, Tien YW, Liang PC, Wei SC, Wong JM.

Pancreas. 2007 Jul;35(1):16-21.

PMID:
17575540
14.

Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.

Wu X, Lu XH, Xu T, Qian JM, Zhao P, Guo XZ, Yang XO, Jiang WJ.

Chin J Dig Dis. 2006;7(3):170-4.

PMID:
16808798
15.

A novel serum metabolomics-based diagnostic approach to pancreatic cancer.

Kobayashi T, Nishiumi S, Ikeda A, Yoshie T, Sakai A, Matsubara A, Izumi Y, Tsumura H, Tsuda M, Nishisaki H, Hayashi N, Kawano S, Fujiwara Y, Minami H, Takenawa T, Azuma T, Yoshida M.

Cancer Epidemiol Biomarkers Prev. 2013 Apr;22(4):571-9. doi: 10.1158/1055-9965.EPI-12-1033.

16.

New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis.

Gold DV, Modrak DE, Ying Z, Cardillo TM, Sharkey RM, Goldenberg DM.

J Clin Oncol. 2006 Jan 10;24(2):252-8.

PMID:
16344318
17.

Can IL-2R alpha be a valuable marker along with CA 19-9 in the diagnosis of chronic pancreatitis and pancreatic cancer?

Kayhan B, Kayhan B, Akdoğan M.

Int J Biol Markers. 2004 Jul-Sep;19(3):196-202.

PMID:
15503821
18.

Identification of potential markers for the detection of pancreatic cancer through comparative serum protein expression profiling.

Ehmann M, Felix K, Hartmann D, Schnölzer M, Nees M, Vorderwülbecke S, Bogumil R, Büchler MW, Friess H.

Pancreas. 2007 Mar;34(2):205-14.

PMID:
17312459
19.

Progress on molecular markers of pancreatic cancer.

Grote T, Logsdon CD.

Curr Opin Gastroenterol. 2007 Sep;23(5):508-14. Review.

PMID:
17762556
20.

Prospective evaluation of the contribution of K-ras mutational analysis and CA 19.9 measurement to cytological diagnosis in patients with clinical suspicion of pancreatic cancer.

Urgell E, Puig P, Boadas J, Capellà G, Queraltó JM, Boluda R, Antonijuan A, Farré A, Lluís F, González-Sastre F, Mora J.

Eur J Cancer. 2000 Oct;36(16):2069-75.

PMID:
11044643

Supplemental Content

Support Center